Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_1
3
75%
Ph not_applicable
1
25%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Recruiting3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (75.0%)
N/A1 (25.0%)

Trials by Status

recruiting375%
unknown125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_1

A Study of ZG005 in Patients With Advanced Solid Tumors

NCT06233292
recruitingphase_1

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

NCT06239298
recruitingphase_1

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

NCT06241235
unknownnot_applicable

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

NCT06233994

Clinical Trials (4)

Showing 4 of 4 trials
NCT06233292Phase 1

A Study of ZG005 in Patients With Advanced Solid Tumors

Recruiting
NCT06239298Phase 1

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Recruiting
NCT06241235Phase 1

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Recruiting
NCT06233994Not Applicable

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4